1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Metered Dose Inhalers Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Metered Dose Inhalers Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Mn)
    4.5. Porter’s Five Forces Analysis
5. Key Insights
    5.1. Respiratory Disease Epidemiology
    5.2. Technological Advancements
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Metered Dose Inhalers Market Analysis and Forecast, by Product Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Product Type, 2017–2031
        6.3.1. Manual Actuated pMDIs
        6.3.2. Breath Actuated pMDIs
    6.4. Market Attractiveness Analysis, by Product Type
7. Global Metered Dose Inhalers Market Analysis and Forecast, by Disease Indication
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Disease Indication, 2017–2031
        7.3.1. Asthma
        7.3.2. COPD
        7.3.3. Others
    7.4. Market Attractiveness Analysis, by Disease Indication
8. Global Metered Dose Inhalers Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Metered Dose Inhalers Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2017–2031
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Metered Dose Inhalers Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Product Type, 2017–2031
        10.2.1. Manual Actuated pMDIs
        10.2.2. Breath Actuated pMDIs
    10.3. Market Value Forecast, by Disease Indication, 2017–2031
        10.3.1. Asthma
        10.3.2. COPD
        10.3.3. Others
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Product Type
        10.6.2. By Disease Indication
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Metered Dose Inhalers Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Product Type, 2017–2031
        11.2.1. Manual Actuated pMDIs
        11.2.2. Breath Actuated pMDIs
    11.3. Market Value Forecast, by Disease Indication, 2017–2031
        11.3.1. Asthma
        11.3.2. COPD
        11.3.3. Others
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Product Type
        11.6.2. By Disease Indication
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Metered Dose Inhalers Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Product Type, 2017–2031
        12.2.1. Manual Actuated pMDIs
        12.2.2. Breath Actuated pMDIs
    12.3. Market Value Forecast, by Disease Indication, 2017–2031
        12.3.1. Asthma
        12.3.2. COPD
        12.3.3. Others
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Product Type
        12.6.2. By Disease Indication
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Metered Dose Inhalers Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product Type, 2017–2031
        13.2.1. Manual Actuated pMDIs
        13.2.2. Breath Actuated pMDIs
    13.3. Market Value Forecast, by Disease Indication, 2017–2031
        13.3.1. Asthma
        13.3.2. COPD
        13.3.3. Others
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Product Type
        13.6.2. By Disease Indication
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Metered Dose Inhalers Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product Type, 2017–2031
        14.2.1. Manual Actuated pMDIs
        14.2.2. Breath Actuated pMDIs
    14.3. Market Value Forecast, by Disease Indication, 2017–2031
        14.3.1. Asthma
        14.3.2. COPD
        14.3.3. Others
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Hospital Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Product Type
        14.6.2. By Disease Indication
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by tier and size of companies)
    15.2. Market Share Analysis, by Company (2021)
    15.3. Company Profiles
        15.3.1. AstraZeneca
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Type Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Cipla Limited
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Type Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Novartis AG
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Type Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Merck & Co., Inc.
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Type Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Sanofi
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Type Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
        15.3.6. Boehringer Ingelheim
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Type Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
        15.3.7. Teva Pharmaceutical Industries Ltd.
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Type Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
        15.3.8. Mylan N.V.
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Type Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
        15.3.9. Hikma Pharmaceuticals plc
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Type Portfolio
            15.3.9.3. Financial Overview
        15.3.10. GlaxoSmithKline
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Product Type Portfolio
            15.3.10.3. Financial Overview
Table 01: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 03: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 07: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 08: North America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 11: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 12: Europe Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 15: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 16: Asia Pacific Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 19: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 20: Latin America Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 23: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
Table 24: Middle East & Africa Metered Dose Inhalers Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			